Friday, September 16, 2011

Finding pathways to cancer progression may lead to identification of targeted therapies

Finding pathways to cancer progression may lead to identification of targeted therapies [ Back to EurekAlert! ] Public release date: 15-Sep-2011
[ | E-mail | Share Share ]

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
267-646-0557
American Association for Cancer Research

SAN FRANCISCO Researchers are working to discover how genes interact with each other to lead to cancer progression. This research is expected to lead the way toward the discovery of new targeted therapies against breast cancer, according to a study presented at the Second AACR International Conference on Frontiers in Basic Cancer Research, held here Sept. 14-18, 2011.

For example, the researchers found that a diuretic used to treat hypertension and edema also stops breast cancer cells from progressing, although this potential treatment is a long way from human trials, said lead researcher Bin Zhang, Ph.D., principal scientist and group leader at Sage Bionetworks in Seattle, Wash.

The researchers analyzed multiple large-scale cancer genomic data sets to find novel pathways and driver genes that help breast cancer progress. They then tested them in the laboratory against various compounds and drugs to see how they would react, explained Zhang.

"We tried to objectively derive a global picture of how genes interact with each other to impact cancer progression so that we could understand holistically the mechanisms underlying this complex disease. Then, we can systematically identify optimal intervention points for drug development," he said.

The researchers found that many genes function as groups corresponding to different pathways, so future targeted therapies would work better if they target more than one pathway. This also gives credence to the idea that using combination therapy against the different genetic pathways might help fight cancer better.

Although they tested breast cancer cells, Zhang said, their methods could be used to test other cancers and even other diseases.

"There is an enormous amount of cancer characterization data available, yet it remains challenging to establish models that predict tumor progression and drug response. We developed complex and advanced algorithms to reconstruct multiscale gene regulatory networks that reveal global patterns of gene interactions in cancer and also detail regulatory maps," he said. "These networks will serve as a blueprint for us to understand cancer progression and develop novel therapeutics."

Zhang and colleagues have found a diuretic used to treat hypertension and edema affected the progression of cancer cells. They predicted and successfully validated its novel effectiveness in preferentially killing cancer cells through inhibiting cell cycle pathways that are responsible for uncontrolled cell proliferation.

Based on their prediction, they believe this drug is as effective in culture as several marketed cancer drugs. However, there is still some time until it can be tested in people, according to Zhang.

###

Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.org

The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes 33,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes seven major peer-reviewed journals: Cancer Discovery; Cancer Research; Clinical Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Prevention Research. AACR journals received 20 percent of the total number of citations given to oncology journals in 2010.


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Finding pathways to cancer progression may lead to identification of targeted therapies [ Back to EurekAlert! ] Public release date: 15-Sep-2011
[ | E-mail | Share Share ]

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
267-646-0557
American Association for Cancer Research

SAN FRANCISCO Researchers are working to discover how genes interact with each other to lead to cancer progression. This research is expected to lead the way toward the discovery of new targeted therapies against breast cancer, according to a study presented at the Second AACR International Conference on Frontiers in Basic Cancer Research, held here Sept. 14-18, 2011.

For example, the researchers found that a diuretic used to treat hypertension and edema also stops breast cancer cells from progressing, although this potential treatment is a long way from human trials, said lead researcher Bin Zhang, Ph.D., principal scientist and group leader at Sage Bionetworks in Seattle, Wash.

The researchers analyzed multiple large-scale cancer genomic data sets to find novel pathways and driver genes that help breast cancer progress. They then tested them in the laboratory against various compounds and drugs to see how they would react, explained Zhang.

"We tried to objectively derive a global picture of how genes interact with each other to impact cancer progression so that we could understand holistically the mechanisms underlying this complex disease. Then, we can systematically identify optimal intervention points for drug development," he said.

The researchers found that many genes function as groups corresponding to different pathways, so future targeted therapies would work better if they target more than one pathway. This also gives credence to the idea that using combination therapy against the different genetic pathways might help fight cancer better.

Although they tested breast cancer cells, Zhang said, their methods could be used to test other cancers and even other diseases.

"There is an enormous amount of cancer characterization data available, yet it remains challenging to establish models that predict tumor progression and drug response. We developed complex and advanced algorithms to reconstruct multiscale gene regulatory networks that reveal global patterns of gene interactions in cancer and also detail regulatory maps," he said. "These networks will serve as a blueprint for us to understand cancer progression and develop novel therapeutics."

Zhang and colleagues have found a diuretic used to treat hypertension and edema affected the progression of cancer cells. They predicted and successfully validated its novel effectiveness in preferentially killing cancer cells through inhibiting cell cycle pathways that are responsible for uncontrolled cell proliferation.

Based on their prediction, they believe this drug is as effective in culture as several marketed cancer drugs. However, there is still some time until it can be tested in people, according to Zhang.

###

Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.org

The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The membership includes 33,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes seven major peer-reviewed journals: Cancer Discovery; Cancer Research; Clinical Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; Molecular Cancer Therapeutics; Molecular Cancer Research; and Cancer Prevention Research. AACR journals received 20 percent of the total number of citations given to oncology journals in 2010.


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Source: http://www.eurekalert.org/pub_releases/2011-09/aafc-fpt091211.php

brady hoke scarlett johansson ali lohan new york election new york election survivor south pacific survivor south pacific

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.